NCT03206086View on ClinicalTrials.gov

Eltrombopag for People With Fanconi Anemia

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 2, 2018

Primary Completion Date

August 1, 2025

Study Completion Date

August 1, 2028

Conditions
Fanconi Anemia
Interventions
DRUG

Eltrombopag

Daily dose - Non-Asian (\>=12): 150 mg Non-Asian (6-11): 75 mg East Asian, South East Asian (\>=12): 75 mg East Asian, South East Asian (6-11): 37.5 mg

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT03206086 - Eltrombopag for People With Fanconi Anemia | Biotech Hunter | Biotech Hunter